Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 1, 2007 Brian Lawler	Dendreon Gains. Why? Shares of the biopharma rise after it announces already expected news.
The Motley Fool March 13, 2008 Brian Lawler	Dendreon Rolls the Dice The pharmaceutical amends a phase 3 study on its lead prostate cancer drug.
The Motley Fool September 13, 2007 Brian Lawler	Don't Bet on the Dendreon Lawsuit A patient advocacy group files a lawsuit attempting to usher Dendreon's prostate cancer drug Provenge onto the market after the FDA has withheld approval. Investors should take note.
The Motley Fool October 29, 2007 Brian Lawler	World's Scariest Stock: Dendreon Investing in the biotech sector is scary enough for most investors. Dendreon's scary future should makes this stock an under-performer.
The Motley Fool May 14, 2007 Brian Lawler	Dendreon Tries to Pick Up the Pieces Dendreon lays out its preliminary plans following a negative FDA regulatory decision. Investors shouldn't necessarily take the smashed-down share price as indicative of a possible biotech value play.
The Motley Fool April 26, 2007 Mike Havrilla	Dendreon Is Worth a Shot Provenge might be approved, which means investors might be rewarded. However, the massive short interest also highlights the tremendous risk in Dendreon.
The Motley Fool January 17, 2007 Brian Lawler	Dendreon in the Fast Lane The FDA speeds up review of Dendreon's leading drug candidate. Investors, take note.
The Motley Fool February 15, 2008 Brian Lawler	Dendreon's Not-So-New Data Development-stage drugmaker Dendreon releases "new data" on lead cancer drug Provenge; unfortunately, the data wasn't the data that investors are waiting for.
The Motley Fool April 4, 2008 Brian Lawler	A Few Thoughts on Dendreon Let's talk about the upcoming Dendreon study results.
The Motley Fool May 9, 2007 Brian Lawler	Diagnosing Dendreon Postmortem The FDA issues an approvable letter for Dendreon's top compound. Investors, take note.
The Motley Fool November 10, 2006 Brian Lawler	Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note.
The Motley Fool April 3, 2007 Brian Lawler	Dendreon's Positive Panel Surprise Shares of the drugmaker jump after a FDA advisory panel finds in favor of its lead cancer compound.
The Motley Fool May 3, 2005 Karl Thiel	Is Dendreon a Rule Breaker? In working to bring the first therapeutic cancer vaccine to market, the company has faced numerous unknowns and challenges. At this stage, it has produced a fair bit of data that investors can use to size up the firm's prospects, but ultimately, you're either a believer or you're not.
The Motley Fool June 5, 2007 Brian Lawler	Dendreon Gets Its Funding Dendreon does a financing to secure its near-term future. Investors who fail to pay attention to relative valuations of the different stocks in the development-stage biotech space do so at their own peril.
The Motley Fool December 14, 2007 Brian Lawler	Ignore the Dendreon Hoopla A Congressional probe request will have no effect on Dendreon or Provenge's odds at making it through the FDA, since it was not the FDA reviewers of the Provenge marketing application that were accused of anything bad.
The Motley Fool July 23, 2007 Brian Lawler	GPC's Date With the FDA A document released by the FDA outlines its concerns with GPC's lead drug. Investors, take note.
The Motley Fool April 5, 2010 Brian Orelli	1 Month to Go! Is Dendreon a Buy? Only if you understand the risks.
The Motley Fool November 16, 2007 Brian Lawler	Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note.
The Motley Fool March 17, 2008 Brian Lawler	Parsing the Details With Dendreon Development-stage drugmaker Dendreon announces that it is changing its pivotal phase 3 clinical trial for its lead drug.
The Motley Fool April 14, 2009 Brian Orelli	Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge.
The Motley Fool May 10, 2006 Brian Lawler	Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note.
The Motley Fool April 29, 2009 Brian Orelli	2 Lessons From Dendreon Traders beware.
The Motley Fool May 16, 2007 Brian Lawler	GPC's Next Cancer Drug? GPC Biotech prepares for its future as it awaits an FDA decision on its lead drug. Investors, take note.
The Motley Fool January 14, 2008 Brian Lawler	Score One for Dendreon and Disclosure A prestigious journal supports Dendreon's potential prostate cancer treatment, and makes a compelling case for more FDA disclosure.
The Motley Fool October 7, 2008 Brian Orelli	Results IMPACT Volatility at Dendreon Dendreon almost hits both a 52-week high and a 52-week low on the day it releases results.
The Motley Fool August 10, 2007 Brian Lawler	GPC Picking Up the Pieces GPC Biotech announced second-quarter financial results last week, in the shadow of a setback; they are awaiting more data on a crucial drug candidate.
The Motley Fool May 10, 2005 Charly Travers	Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in?
BusinessWeek October 6, 2003 Gene G. Marcial	Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer.
The Motley Fool August 9, 2010 Brian Orelli	Dendreon's in Trouble Provided you call a slap on the wrist from the FDA "trouble."
The Motley Fool September 22, 2010 Brian Orelli	A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead.
The Motley Fool July 25, 2007 Brian Lawler	GPC Must Wait An advisory panel recommends against approving GPC's lead drug right now. Investors, take note.
The Motley Fool July 18, 2007 Brian Lawler	More Misery for Neurochem It's hard to find another drug developer that has mishandled its correspondence with investors about its drug candidates as badly as Neurochem has over the past year.
The Motley Fool March 19, 2007 Brian Lawler	Is Dendreon Doomed? A pivotal FDA regulatory meeting approaches for the development-stage pharma. Investors, take note.
The Motley Fool May 13, 2011 Brian Orelli	FDA Advisory Panel Positive! Shares Punished. Despite the positive recommendation, investors aren't convinced BioMimetic's Augment will be approved.
The Motley Fool November 4, 2010 Brian Orelli	Are Monthly Numbers Necessary, Dendreon? Focus on what's important.
The Motley Fool September 28, 2010 Brian Orelli	It's Up! It's Down! It's Dendreon! The joys of biotech.
The Motley Fool October 31, 2008 Brian Orelli	World's Scariest Stock: Dendreon The fear of the unknown makes investing scary, and things don't get much more unknown than the future of biotech company Dendreon.
The Motley Fool April 17, 2007 Matt Koppenheffer	The 5-Sigma Report A look at the stocks that saw serious volatility last week. Dyax... SLM Corp... IPSCO... Dendreon... Manor Care...
The Motley Fool April 30, 2010 Brian Orelli	Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it?
The Motley Fool July 29, 2010 Brian Orelli	Forget Respect -- Dendreon Needs Sales! Dendreon's Provenge was approved months ago, but the data from the clinical trial supporting the FDA's decision was finally published in the New England Journal of Medicine this week.
The Motley Fool May 18, 2009 Brian Orelli	Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price.
The Motley Fool July 22, 2005 Karl Thiel	Cancer Drug: A Shot at Success Cancer vaccine pioneer Dendreon delivered news yesterday that its investors have been anxiously awaiting: final three-year survival data from a phase 3 study of Provenge, the company's flagship prostate cancer vaccine.
The Motley Fool August 18, 2010 Travers & Greer	Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon?
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool June 19, 2009 Brian Orelli	Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk.
The Motley Fool November 16, 2010 Luke Timmerman	Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug.
The Motley Fool June 18, 2009 Daniel Harrison	Is Dendreon Just a Dot-Com Story at This Price? The stock has had a really good year, but now it may be time to lock in the gains.
The Motley Fool February 7, 2011 Brian Orelli	Zibotentan Stopped, Long Live Provenge (for Now) Dendreon is looking good although it's not out of the woods yet.
The Motley Fool September 24, 2007 Brian Lawler	Encysive Hears the Voice of Reason To please the FDA, Encysive Pharmaceuticals announces it is planning an additional phase 3 trial to try and bring its lead drug, Thelin, to market in the United States.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.